


Atezolizumab IMvigor211

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Atezolizumab IMvigor211

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: Treatment of patients with locally advanced or metastatic UC after prior platinum-containing ChT
Experimental Arm: Atezolizumab
Control Arm: ChT (vinflunine, paclitaxel or docetaxel)

